Document Detail

Long-term treatment of acromegaly with octreotide (Sandostatin).
MedLine Citation:
PMID:  2192978     Owner:  NLM     Status:  MEDLINE    
Sixteen patients with acromegaly have been treated with octreotide [100 micrograms twice daily to 200 micrograms 3 times daily according to growth hormone (GH) response] for between 3 and 44 months. The mean serum GH concentrations fell from 39.3 mU/l before treatment to 10.5 mU/l on day 1 of treatment and, with continued treatment (and higher doses in 8 of 16 patients), to 7.9 mU/l. In 2 patients there was no GH suppression. GH suppression after the first administration of octreotide appeared to predict long-term response. Pre-treatment serum insulin-like growth factor 1 levels were elevated in 11 of 12 patients investigated, but were normalized on continued octreotide therapy in 10 of 12. Octreotide suppressed prolactin secretion in all 6 hyperprolactinaemic patients. Steatorrhoea occurred in 15 of 16 patients at initiation of treatment, but resolved in all within 7 days. Two patients developed gallstones. In summary, octreotide is a safe and effective treatment for acromegaly, producing clinical and biochemical improvement in up to 90% of patients. Octreotide is a valuable adjunctive treatment where surgery has failed and also in those with contra-indications to surgery.
M D Page; M E Millward; M Hourihan; R Hall; N F Scanlon
Related Documents :
22921858 - No diversion in western massachusetts.
14768178 - The assessment of cabergoline efficacy and tolerability in patients with pituitary prol...
21035068 - Prevalence and clinical characteristics of congenital dacryocystocele.
23424678 - The impact of art on the economic outcomes of people living with hiv/aids.
10325678 - Temporomandibular joint ankylosis: the egyptian experience.
12792338 - Atlantoaxial stabilization: clinical comparison of posterior cervical wiring technique ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Hormone research     Volume:  33 Suppl 1     ISSN:  0301-0163     ISO Abbreviation:  Horm. Res.     Publication Date:  1990  
Date Detail:
Created Date:  1990-07-27     Completed Date:  1990-07-27     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0366126     Medline TA:  Horm Res     Country:  SWITZERLAND    
Other Details:
Languages:  eng     Pagination:  20-30; discussion 30-1     Citation Subset:  IM    
Department of Medicine, University of Wales College of Medicine, Cardiff, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acromegaly / drug therapy*
Blood Glucose
Growth Hormone / blood
Insulin / blood
Insulin-Like Growth Factor I / analysis
Middle Aged
Octreotide / adverse effects,  therapeutic use*
Pituitary Neoplasms / complications
Prolactin / blood
Thyroid Gland / drug effects
Thyrotropin / biosynthesis
Thyroxine / biosynthesis
Reg. No./Substance:
0/Blood Glucose; 11061-68-0/Insulin; 67763-96-6/Insulin-Like Growth Factor I; 7488-70-2/Thyroxine; 83150-76-9/Octreotide; 9002-62-4/Prolactin; 9002-71-5/Thyrotropin; 9002-72-6/Growth Hormone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Lectin-binding sites in the retina of the pig, baboon and cat.
Next Document:  Application of the polymerase chain reaction to the diagnosis of human genetic disease.